US Patent No. 8,912,157

CuRNA has been awarded US Patent No. 8,912,157, "Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene."

More Like This

Feb 22, 2017

N-of-One RapidInsights for Illumina's Trusight Tumor

N-of-One has launched the RapidInsights for Illumina TruSight Tumor 170 (TST170) panel. RapidInsights is a fully automated interpretation solution that will read bioinformatics output of the genomic variants from the TST170 panel in minutes. Results from the panel are based on the medical literature, guidelines, and clinical trials to determine the best therapies and/or trials for the patient. The solution will be available through the Philips' Intellispace Genomics solution, the company said.